1153P Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers
A. Savinainen(BioClinica (United States)), Henry Mok(Baylor College of Medicine), A. Sutton(Universidad Mariana), Ahmed Salih(Universidad Mariana), Lijun Wu(Soochow University), Aliza Zidell(Hackensack University Medical Center), Xiayu Xu(Universidad Mariana), K. Lee(Universidad Mariana), L. Tavera(Universidad Mariana), Karim Nabi(Universidad Mariana), Zheng Wang(Shanghai Jiao Tong University), Zheng Ma(Beijing Computational Science Research Center), Min Wan(Nanchang University), Jiangang Xu(Universidad Mariana), Jason L.J. Dearling(Universidad Mariana), T. Bruton(Universidad Mariana), J. Cupido(Universidad Mariana), Apurva Chonkar(Universidad Mariana), C. Huang(Universidad Mariana)
Cited by 2
Related Papers
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry
|Journal of Clinical Oncology|2017|358
Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
|Clinical Cancer Research|2018|355
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition
|Clinical Cancer Research|2011|146
Perspective on CFD studies of coronary artery disease lesions and hemodynamics: A review
|International Journal for Numerical Methods in Biomedical Engineering|2014|99